

## DECLARATION FOR PATENT APPLICATION

As a named inventor, I hereby declare that:

My residence, post office address and citizenship is as stated below next to my name;

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: IMMUNOLOGICAL CONTROL OF  $\beta$ -AMYLOID LEVELS *IN VIVO*, the specification of which

☐ is attached hereto.

☒ was filed on June 15, 2000 as Application Serial Number 09/594,366.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

### Prior Foreign Application(s)

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Country	Application Number	Date of Filing (day, month, year)	Date of Issue (day, month, year)	Priority Claimed Under 35 U.S.C. 119
				Yes <input type="checkbox"/> No <input type="checkbox"/>
				Yes <input type="checkbox"/> No <input type="checkbox"/>

### Prior United States Provisional Application(s)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below:

Application Number	Filing Date
60/139,408	June 16, 1999

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

Application Serial Number	Date of Filing (day, month, year)	Status - Patented, Pending, Abandoned

Kevin M. Farrell, 35,505

All correspondence and telephone communications should be addressed to Kevin M. Farrell, Farrell & Associates, P.C., P.O. Box 999, York Harbor, ME 03911, telephone number (207) 363-0558, which is also the address and telephone number of each of the above listed attorneys.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

BBRI\CUR\2004.DEC

same

## ASSIGNMENT

Whereas, I, Victor Raso, have invented a certain improvement in  
IMMUNOLOGICAL CONTROL OF  $\beta$ -AMYLOID LEVELS *IN VIVO* described in United  
States Patent Application No.: 09/594,366, filed June 15, 2000;

Whereas, Boston Biomedical Research Institute (hereinafter "ASSIGNEE"), a  
corporation organized and existing under the laws of Massachusetts, and having a usual place  
of business at 64 Grove Street, Watertown, MA 02472, desires to acquire an interest therein  
in accordance with agreements duly entered into with me;

Now, therefore, to all whom it may concern be it known that for and in consideration  
of the said agreements and of other good and valuable consideration, the receipt of which is  
hereby acknowledged, I have sold, assigned and transferred and by these presents do hereby  
sell, assign and transfer unto said ASSIGNEE, its successors, assigns and legal representa-  
tives, the entire right, title and interest in and throughout the United States of America, its  
territories and all foreign countries, in and to the said invention as described in said applica-  
tion, together with the entire right, title and interest in and to the said application and such  
Letters Patent as may issue thereon; said invention, application and Letters Patent to be held  
and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns  
and legal representatives, to the full end of the term for which said Letters Patent may be  
granted as fully and entirely as the same would have been held by me had this assignment  
and sale not been made; I hereby convey all rights arising under or pursuant to any and all  
international agreements, treaties or laws relating to the protection of industrial property by  
filing any such applications for Letters Patent. I hereby acknowledge that this assignment,  
being of the entire right, title and interest in and to said invention, carries with it the right in  
ASSIGNEE to apply for and obtain from competent authorities in all countries of the world  
any and all Letters Patent by attorneys and agents of ASSIGNEE selection and the right to  
procure the grant of all such Letters Patent to ASSIGNEE for its own name as assignee of  
the entire right, title and interest therein;

AND, I hereby further agree for myself and my executor and administrator to execute  
upon request any other lawful documents and likewise to perform any other lawful acts  
which may be deemed necessary to secure fully the aforesaid invention to said ASSIGNEE,  
its successors, assigns and legal representatives, but at its or their expense and charges,  
including the execution of applications for patents in foreign countries, and the execution of  
substitution, reissue, divisional or continuation applications and preliminary or other state-  
ments and the giving of testimony in any interference or other proceeding in which said  
invention or any application or patent directed thereto may be involved;

AND, I do hereby authorize and request the Commissioner of Patents of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said ASSIGNEE, its successors, assigns, and legal representatives;

Inventor Signature

Vendor Signature  
Victor Rasco

## Victor Raso

Date Signed

8/9/00

Witness Signature

Sharon S. Lehrer

J. S. Lehrer

Date Signed

879/00

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS  
(37 CFR 1.9(f) & 1.27(d)) - NONPROFIT ORGANIZATION

DOCKET NUMBER  
BBRI-2004

Applicant or Patentee: Victor Raso

Serial or Patent No.:

Filed or Issued:

Title: IMMUNOLOGICAL CONTROL OF  $\beta$ -AMYLOID LEVELS *IN VIVO*

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: Boston Biomedical Research Institute

ADDRESS OF ORGANIZATION: 20 Staniford Street  
Boston, MA 02114

TYPE OF NONPROFIT ORGANIZATION:

- ☐ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
- ☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE  
(26 USC 501(a) and 501(c)(3))
- ☒ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF  
STATE OF THE UNITED STATES OF AMERICA  
(NAME OF STATE \_\_\_\_\_)  
(CITATION OF STATUTE \_\_\_\_\_)
- ☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE  
(26 USC 501(a) and 501(c)(3)) IF LOCATED IN THE UNITED STATES OF AMERICA
- ☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE  
OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED  
STATES OF AMERICA  
(NAME OF STATE \_\_\_\_\_)  
(CITATION OF STATUTE \_\_\_\_\_)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:

- ☒ the specification filed herewith with the title as listed above.
- ☐ the application identified above.
- ☐ the patent identified above.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above-identified invention. If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention must file separate verified statements averring to their status as small entities and that no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization having any rights in the invention is listed below:

  X   no such person, concern, or organization exists.  
       each such person, concern, or organization is listed below.

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Kathleen Morgan, Ph.D.

TITLE IN ORGANIZATION: Director

ADDRESS OF PERSON SIGNING: Boston Biomedical Research Institute  
20 Staniford Street  
Boston, MA 02114

SIGNATURE KG May DATE 6-16-99